



LUBISCH et al,

Serial No. 09/830,992

REMARKS

The claims pending are 1-26. Claims 2, 3 and 7 have been amended to correct additional typographical errors in applicants supplemental amendment of September 5, 2002. The errors were inadvertent, and any inconvenience caused thereby, are sincerely regretted.

Accordingly, the next office action -- preferably a notice of allowance -- is awaited.

To the extent necessary, applicant(s) petition for an Extension of Time under 37 CFR 1.136. Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,
KEIL & WEINKAUF

Norman G. Torchin

Norman G. Torchin
Reg. No. 34,068

1350 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100
NGT/mks



LUBISCH

Serial No: 09/830,992

RECEIVED
SEP 23 2002
TECH CENTER 1600/2900

VERSION WITH MARKINGS TO SHOW CHANGES MADE IN THE CLAIMS

Please amend claims 2, 3, and 7 as follows:

2. (thrice amended) A compound of the formula I or II as claimed in claim 1 in which

R^1 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, it also being possible for one C atom of the alkyl radical to carry OR^{11} or a group R^5 , where

R^{11} is hydrogen or C_1 - C_4 -alkyl, and

R^2 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C_1 - C_6 -alkyl, nitro, CF_3 , CN , $NR^{22}R^{23}$, $NH-CO-R^{21}$, OR^{21} , where

R^{21} and R^{22} are, independently of one another, hydrogen or C_1 - C_4 -alkyl, and

R^{23} is hydrogen, C_1 - C_4 -alkyl or phenyl, and

R^3 is $-O-(CH_2)_o-(CHR^{31})_m-(CH_2)_n-G$, where

R^{31} is hydrogen, C_1 - C_4 -alkyl, OH and $O-C_1$ - C_4 -alkyl,

m, o are, independently of one another, 0, 1 or 2, and


n is 1, 2, 3 or 4 and

R^4 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, chlorine, bromine, fluorine, nitro, cyano, NR^{41} , R^{42} , $NH-CO-R^{43}$, and OR^{41} where

R^{41} and R^{42} are, independently of one another, hydrogen or C_1 - C_4 -alkyl, and

R^{43} is C_1 - C_4 -alkyl or phenyl, and

G is $NR^{51}R^{52}$ or one of the following radicals





RECEIVED
SEP 23 2002
TECH CENTER 1600/2900


LUBISCH et al.

Serial No. 09/830,992


where

R^{51} is hydrogen and branched and unbranched C_1 - C_6 -alkyl, and

R^{52} is hydrogen, branched and unbranched C_1 - C_6 -alkyl phenyl,



R^{53} is branched or unbranched O - C_1 - C_6 -alkyl, phenyl, branched or unbranched C_1 - C_4 -alkyl-phenyl, where one hydrogen in the C_1 - C_6 -alkyl radical in R^{52} and R^{53} are, independently of one another, optionally substituted by one of the following radicals: OH, O - C_1 - C_4 -alkyl, cyclohexyl, cyclopentyl, tetrahydronaphthyl, cyclopropyl, cyclobutyl, cycloheptyl, naphthyl and phenyl, where the carbocycles of the R^{52} and R^{53} radicals may also, independently of one another, carry one or two of the following radicals: branched or unbranched C_1 - C_6 -alkyl, branched or unbranched O - C_1 - C_4 -alkyl, OH, F, Cl, Br, I, CF_3 , NO_2 , NH_2 , CN, COOH, COOC_1 - C_4 -alkyl, C_1 - C_4 -alkylamino, CCl_3 , C_1 - C_4 -dialkylamino, SO_2 - C_1 - C_4 -alkyl, SO_2 phenyl, CONH_2 , CONH - C_1 - C_4 -alkyl, CONH phenyl, CONH - C_1 - C_4 -alkyl-phenyl, NHSO_2 - C_1 - C_4 -alkyl, NHSO_2 phenyl, S - C_1 - C_4 -alkyl,



CHO, CH_2 - O - C_1 - C_4 -alkyl, $-\text{CH}_2$ - O - C_1 - C_4 -alkyl-phenyl, $-\text{CH}_2$ OH, $-\text{SO}$ - C_1 - C_4 -alkyl, $-\text{SO}$ - C_1 - C_4 -alkyl-phenyl, SO_2NH_2 , $-\text{SO}_2\text{NH}$ - C_1 - C_4 -alkyl and two radicals



LUBISCH et al.,

Serial No. 09/830,992

form a bridge $-O-(CH_2)_{1,2}-O-$,

or a tautomeric form, a possible enantiomeric or diastereomeric form, a prodrug or pharmacologically tolerated salt thereof.

3. (four times amended) A compound of the formula I or II as claimed in claim 1 in which

R^1 is hydrogen, branched and unbranched C_1-C_6 -alkyl, it also being possible for one C atom of the alkyl radical to carry OR^{11} or a group R^5 , where




R^{11} is hydrogen or C_1-C_4 -alkyl, and

R^2 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C_1-C_6 -alkyl, nitro, CF_3 , CN, $NR^{22}R^{23}$, $NH-CO-R^{21}$, OR^{21} , where

R^{21} and R^{22} independently of one another are hydrogen or C_1-C_4 -alkyl and

R^{23} is hydrogen, C_1-C_4 alkyl or phenyl

R^3 is



and

R^{31} is hydrogen, CHO and $[-(CH_2)_o-(CHR^{32})_m-(CH_2)_n-R^5]-(CH_2)_o-(CHR^{32})_m-(CH_2)_n-G$, where R^{32} is hydrogen, C_1-C_4 -alkyl, OH and $O-C_1-C_4$ -alkyl, m, o independently of one another are 0, 1 or 2 and n is 1, 2, 3 or 4, and



LUBISCH et al.,


Serial No. 09/830,992

R^4 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, chlorine, bromine, fluorine, nitro, cyano, NR^{41} [,] R^{42} , $NH-CO-R^{43}$, OR^{41} , where

R^{41} and R^{42} independently of one another are hydrogen or C_1 - C_4 -alkyl and

R^{43} is C_1 - C_4 -alkyl or phenyl, and

G is $NR^{51}R^{52}$ or one of the radicals below



where


R^{51} is hydrogen and branched and unbranched and C_1 - C_6 -alkyl and

R^{52} is hydrogen, $COCH_3$, $CO-O-C_1-C_4$ -alkyl, $COCF_3$, branched and unbranched C_1 - C_6 -alkyl, it being possible for one hydrogen of the C_1 - C_6 -alkyl radical to be substituted by one of the following radicals: OH, $O-C_1-C_4$ -alkyl and phenyl and for the phenyl ring also to carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C_1 - C_4 -alkyl, nitro, amino, C_1 - C_4 -alkylamino, C_1 - C_4 -dialkylamino, OH, $O-C_1-C_4$ -alkyl, CN, SO_2 - C_1 - C_4 -alkyl,

or a tautomeric form, a possible enantiomeric or diastereomeric form, a prodrug or pharmacologically tolerated salt thereof.

7. (twice amended) A compound as claimed in claim 1 where


(i) for R^3 being



R^{31} is hydrogen or $-(CH_2)_p-G$, where

p is 1 or 2 and


(ii) for R^3 being



R^{31} is hydrogen or $-(CH_2)_p-R^5$, where

p is 1 or 2 and

and (iii) for R^3 being



$[R^{52}$ may be hydrogen, branched and unbranched C_1 - C_6 -alkyl, where one hydrogen of the C_1 - C_6 -alkyl radical may be substituted by one of the following radicals: OH, O- C_1 - C_4 -alkyl and phenyl, and where the phenyl ring may also carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C_1 - C_4 -alkyl, nitro, amino, C_1 - C_4 -alkylamino, C_1 - C_4 -dialkylamino, OH, O- C_1 - C_4 -alkyl, CN, SO_2 - C_1 - C_4 -alkyl;]

where R^{52} is hydrogen, branched and unbranched C_1 - C_6 -alkyl, where one hydrogen



LUBISCH et al. Serial No. 09/830,992

of the C₁-C₆-alkyl radical may be substituted by one of the following radicals: OH, O-C₁-C₄-alkyl and phenyl, and where the phenyl ring may also carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C₁-C₄-alkyl, nitro, amino, C₁-C₄-alkylamino, C₁-C₄-dialkylamino, OH, O-C₁-C₄-alkyl, CN, SO₂-C₁-C₄-alkyl.





LUBISCH et al.,

Serial No. 09/830,992

COPY OF ALL CLAIMS

1. A compound of the formula I or II



in which

R¹ is hydrogen, or branched and unbranched C₁-C₆-alkyl, it also being possible for one C atom of the alkyl radical to carry OR¹¹ or a group R⁵, where R¹¹ is hydrogen or C₁-C₄-alkyl, and

R² is hydrogen, chlorine, bromine, iodine, fluorine, CF₃, nitro, NHCOR²¹, NR²²R²³, OH, O-C₁-C₄-alkyl, O-C₁-C₄-alkylphenyl, NH₂, CN, a straight or branched C₁ - C₆-alkyl, OR²¹ or phenyl, it also being possible for the phenyl rings to be substituted by at most two radicals R²⁴, and R²¹ and R²² independently of one another are hydrogen or C₁-C₄-alkyl and R²³ is hydrogen, C₁-C₄-alkyl or phenyl, and R²⁴ is OH, C₁-C₆-alkyl, O-C₁-C₄-alkyl, chlorine, bromine, iodine, fluorine, CF₃, nitro or NH₂, and

x may be 0, 1 or 2 and



LUBISCH et al.,

Serial No. 09/830,992

- R^3 is $-D-(F^1)_p-(E)_q-(F^2)_r-G$, where p , q and r may not simultaneously be 0, or is $-E-(D)_u-(F^2)_s-(G)_v$, it also being possible for the radical E to be substituted by one or two radicals A , and if $v = 0$, E is imidazole, pyrrole, pyridine, pyrimidine, piperazine, pyrazine, pyrrolidine or piperidine, or R^3 is B and
- R^4 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C_1-C_6 -alkyl, OH, nitro, CF_3 , CN, $NR^{41}R^{42}$, $NH-CO-R^{43}$, or $O-C_1-C_4$ -alkyl, where R^{41} and R^{42} independently of one another are hydrogen or C_1-C_4 -alkyl and R^{43} is hydrogen, C_1-C_4 -alkyl, C_1-C_4 -alkylphenyl or phenyl, and
- D is S or O
- E is phenyl, imidazole, pyrrole, thiophene, pyridine, pyrimidine, piperazine, pyrazine, furan, thiazole, isoxazole, pyrrolidine, piperidine, or trihydroazepine and
- F^1 is a chain of 1 to 8 carbon atoms, it also being possible for one carbon atom of the chain to carry an OH or $O-C_1-C_4$ -alkyl group and
- F^2 is a chain of 1 to 8 carbon atoms, it also being possible for one carbon atom of the chain to carry an OH or $O-C_1-C_4$ -alkyl group and
- p may be 0 or 1
- q may be 0 or 1, and
- r may be 0 or 1 and
- s may be 0 or 1
- u may be 0 or 1




LUBISCH et al.

Serial No. 09/830,992

v may be 0 or 1


G may be $\text{NR}^{51}\text{R}^{52}$ or



and

R^{51} is hydrogen or branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, or $(\text{CH}_2)_t\text{-K}$ and

R^{52} is hydrogen, branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, phenyl,




in which

R^{53} may be branched or unbranched $\text{O-C}_1\text{-C}_6\text{-alkyl}$, phenyl, or branched or unbranched $\text{C}_1\text{-C}_4\text{-alkylphenyl}$, where in the case of R^{52} and R^{53} ,

independently of one another, one hydrogen of the $\text{C}_1\text{-C}_6\text{-alkyl}$ radical may be substituted by one of the following radicals: OH , $\text{O-C}_1\text{-C}_4\text{-alkyl}$, cyclohexyl, cyclopentyl, tetrahydronaphthyl, cyclopropyl, cyclobutyl, cycloheptyl, naphthyl and phenyl, it also being possible for the carbocycles of the radicals R^{52} and R^{53} independently of one another to carry one or two of the following radicals: branched or unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, branched or unbranched $\text{O-C}_1\text{-C}_4\text{-alkyl}$,


OH, F, Cl, Br, I, CF₃, NO₂, NH₂, CN, COOH, COOC₁-C₄-alkyl, C₁-C₄-alkylamino, CCl₃, C₁-C₄-dialkylamino, SO₂-C₁-C₄-alkyl, SO₂phenyl, CONH₂, CONH-C₁-C₄-alkyl, CONHphenyl, CONH-C₁-C₄-alkylphenyl, NHSO₂-C₁-C₄-alkyl, NHSO₂phenyl, S-C₁-C₄-alkyl,



CHO, CH₂-O-C₁-C₄-alkyl, -CH₂O-C₁-C₄-alkylphenyl, -CH₂OH, -SO-C₁-C₄-alkyl, -SO-C₁-C₄-alkylphenyl, -SO₂NH₂, -SO₂NH-C₁-C₄-alkyl

or two radicals form a bridge -O-(CH₂)_{1,2}-O-,

B may be




and

A may be hydrogen, chlorine, bromine, iodine, fluorine, CF₃, nitro, OH, O-C₁-C₄-alkyl, O-C₁-C₄-alkylphenyl, NH₂, branched and unbranched C₁-C₆-alkyl, CN, or NH-CO-R³³, where R³³ is hydrogen, C₁-C₄-alkyl or phenyl and

t is 0,1,2,3, or 4 and

K is a phenyl optionally having at most two substituents on the ring, R^{k1} and/or R^{k2} are any of the radicals defined for R^{41} and R^{42} , respectively, or NH-C₁-C₄-alkylphenyl, pyrrolidine, piperidine, 1,2, 5, 6-tetrahydropyridine, morpholine, trihydroazepine, piperazine, which may also be substituted by an alkyl radical C₁-C₆-alkyl, or homopiperazine, which may also be substituted by an alkyl radical C₁-C₆-alkyl, and

R^5 may be hydrogen, C₁-C₆-alkyl, or NR^7R^9 and



and

R^7 is hydrogen, C₁-C₆-alkyl, C₁-C₄-alkylphenyl, or phenyl, it also being possible for the rings to be substituted by up to two radicals R^{71} , and

R^{71} is OH, C₁-C₆-alkyl, O-C₁-C₄-alkyl, chlorine, bromine, iodine, fluorine, CF₃, nitro, or NH₂, and

R^8 is hydrogen, C₁-C₆-alkyl, phenyl, or C₁-C₄-alkylphenyl, it also being possible for the ring to be substituted by up to two radicals R^{81} , and

R^{81} is OH, C₁-C₆-alkyl, O-C₁-C₄-alkyl, chlorine, bromine, iodine, fluorine, CF₃,

nitro, or NH_2 and

R^9 is hydrogen, COCH_3 , $\text{CO-O-C}_1\text{-C}_4\text{-alkyl}$, COCF_3 , branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, it being possible for one or two hydrogens of the $\text{C}_1\text{-C}_6\text{-alkyl}$ radical to be substituted in each case by one of the following radicals: OH , $\text{O-C}_1\text{-C}_4\text{-alkyl}$ and phenyl, and for the phenyl ring also to carry one or two of the following radicals: iodine, chlorine, bromine, fluorine, branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, nitro, amino, $\text{C}_1\text{-C}_4\text{-alkylamino}$, $\text{C}_1\text{-C}_4\text{-dialkylamino}$, OH , $\text{O-C}_1\text{-C}_4\text{-alkyl}$, CN , CF_3 , or $\text{SO}_2\text{-C}_1\text{-C}_4\text{-alkyl}$,

or a tautomeric form, a possible enantiomeric or diastereomeric form, a prodrug or pharmacologically tolerated salt thereof.

2. A compound of the formula I or II as claimed in claim 1 in which

R^1 is hydrogen, branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, it also being possible for one C atom of the alkyl radical to carry OR^{11} or a group R^5 , where

R^{11} is hydrogen or $\text{C}_1\text{-C}_4\text{-alkyl}$, and

R^2 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, nitro, CF_3 , CN , $\text{NR}^{22}\text{R}^{23}$, NH-CO-R^{21} , OR^{21} , where

R^{21} and R^{22} are, independently of one another, hydrogen or $\text{C}_1\text{-C}_4\text{-alkyl}$, and

R^{23} is hydrogen, $\text{C}_1\text{-C}_4\text{-alkyl}$ or phenyl, and

R^3 is $-\text{O}-(\text{CH}_2)_o-(\text{CHR}^{31})_m-(\text{CH}_2)_n-\text{G}$, where

R^{31} is hydrogen, $\text{C}_1\text{-C}_4\text{-alkyl}$, OH and $\text{O-C}_1\text{-C}_4\text{-alkyl}$,

m, o are, independently of one another, 0, 1 or 2, and



RECEIVED
SEP 23 2002
TECH CENTER 1600/2900

LUBISCH et al., Serial No. 09/830,992


n is 1, 2, 3 or 4 and

R^4 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, chlorine, bromine, fluorine, nitro, cyano, $NR^{41}R^{42}$, $NH-CO-R^{43}$, OR^{41} where

R^{41} and R^{42} are, independently of one another, hydrogen or C_1 - C_4 -alkyl, and

R^{43} is C_1 - C_4 -alkyl or phenyl, and


G is $NR^{51}R^{52}$ or one of the following radicals



where


R^{51} is hydrogen and branched and unbranched C_1 - C_6 -alkyl, and

R^{52} is hydrogen, branched and unbranched C_1 - C_6 -alkyl phenyl,



R^{53} is branched or unbranched $O-C_1$ - C_6 -alkyl, phenyl, branched or unbranched C_1 - C_4 -alkyl-phenyl, where one hydrogen in the C_1 - C_6 -alkyl radical in R^{52} and R^{53} are, independently of one another, optionally substituted by one of the following radicals: OH, $O-C_1$ - C_4 -alkyl, cyclohexyl, cyclopentyl, tetrahydronaphthyl, cyclopropyl, cyclobutyl, cycloheptyl, naphthyl and phenyl,

where the carbocycles of the R^{52} and R^{53} radicals may also, independently of one another, carry one or two of the following radicals: branched or unbranched C_1 - C_6 -alkyl, branched or unbranched O - C_1 - C_4 -alkyl, OH , F , Cl , Br , I , CF_3 , NO_2 , NH_2 , CN , $COOH$, $COOC_1$ - C_4 -alkyl, C_1 - C_4 -alkylamino, CCl_3 , C_1 - C_4 -dialkylamino, SO_2 - C_1 - C_4 -alkyl, SO_2 phenyl, $CONH_2$, $CONH$ - C_1 - C_4 -alkyl, $CONH$ phenyl, $CONH$ - C_1 - C_4 -alkyl-phenyl, $NHSO_2$ - C_1 - C_4 -alkyl, $NHSO_2$ phenyl, S - C_1 - C_4 -alkyl,



CHO , CH_2 - O - C_1 - C_4 -alkyl, $-CH_2O$ - C_1 - C_4 -alkyl-phenyl, $-CH_2OH$, $-SO$ - C_1 - C_4 -alkyl, $-SO$ - C_1 - C_4 -alkyl-phenyl, SO_2NH_2 , $-SO_2NH$ - C_1 - C_4 -alkyl and two radicals form a bridge $-O-(CH_2)_{1,2}-O-$,

or a tautomeric form, a possible enantiomeric or diastereomeric form, a prodrug or pharmacologically tolerated salt thereof.

3. A compound of the formula I or II as claimed in claim 1 in which

R^1 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, it also being possible for one C atom of the alkyl radical to carry OR^{11} or a group R^5 , where

R^{11} is hydrogen or C_1 - C_4 -alkyl, and

R^2 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C_1 - C_6 -alkyl, nitro, CF_3 , CN , $NR^{22}R^{23}$, $NH-CO-R^{21}$, OR^{21} , where



RECEIVED
SEP 23 2002
TECH CENTER 1600/2900




LUBISCH et al., Serial No. 09/830,992

R^{21} and R^{22} independently of one another are hydrogen or

C_1 - C_4 -alkyl and

R^{23} is hydrogen, C_1 - C_4 alkyl or phenyl

R^3 is



and






R^{31} is hydrogen, CHO and $-(CH_2)_o-(CHR^{32})_m-(CH_2)_n-G$, where R^{32} is hydrogen, C_1 - C_4 -alkyl, OH and O- C_1 - C_4 -alkyl, m, o independently of one another are 0, 1 or 2 and n is 1, 2, 3 or 4, and

R^4 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, chlorine, bromine, fluorine, nitro, cyano, $NR^{41}R^{42}$, $NH-CO-R^{43}$, OR^{41} , where

R^{41} and R^{42} independently of one another are hydrogen or C_1 - C_4 -alkyl and

R^{43} is C_1 - C_4 -alkyl or phenyl, and

G is $NR^{51}R^{52}$ or one of the radicals below




where

R^{51} is hydrogen and branched and unbranched and C_1 - C_6 -alkyl and

R^{52} is hydrogen, COCH_3 , $\text{CO-O-C}_1\text{-C}_4\text{-alkyl}$, COCF_3 , branched and unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, it being possible for one hydrogen of the $\text{C}_1\text{-C}_6\text{-alkyl}$ radical to be substituted by one of the following radicals: OH, $\text{O-C}_1\text{-C}_4\text{-alkyl}$ and phenyl and for the phenyl ring also to carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched $\text{C}_1\text{-C}_4\text{-alkyl}$, nitro, amino, $\text{C}_1\text{-C}_4\text{-alkylamino}$, $\text{C}_1\text{-C}_4\text{-dialkylamino}$, OH, $\text{O-C}_1\text{-C}_4\text{-alkyl}$, CN, $\text{SO}_2\text{-C}_1\text{-C}_4\text{-alkyl}$,


or a tautomeric form, a possible enantiomeric or diastereomeric form, a prodrug or pharmacologically tolerated salt thereof.

4. A compound as claimed in claim 1, where R^2 is in position 3 and R^3 is in position 4 or R^2 is in position 4 and R^3 is in position 3 relative to the benzimidazole ring.
5. A compound as claimed in claim 1, where R^1 and R^4 are hydrogen.
6. A compound as claimed in claim 1, where
 R^2 is hydrogen, branched or unbranched $\text{C}_1\text{-C}_6\text{-alkyl}$, nitro, CN, NH_2 , $\text{O-C}_1\text{-C}_4\text{-alkyl}$.
7. A compound as claimed in claim 1 where
(i) for R^3 being




R^{31} is hydrogen or $-(\text{CH}_2)_p\text{-G}$, where

p is 1 or 2 and



LUBISCH et al., Serial No. 09/830,992


(ii) for R^3 being



R^{31} is hydrogen or $-(CH_2)_p-R^5$, where

p is 1 or 2 and

and (iii) for R^3 being



where R^{52} is hydrogen, branched and unbranched C_1 - C_6 -alkyl, where one hydrogen of the C_1 - C_6 -alkyl radical may be substituted by one of the following radicals: OH, O- C_1 - C_4 -alkyl and phenyl, and where the phenyl ring may also carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C_1 - C_4 -alkyl, nitro, amino, C_1 - C_4 -alkylamino, C_1 - C_4 -dialkylamino, OH, O- C_1 - C_4 -alkyl, CN, SO_2 - C_1 - C_4 -alkyl.

8. A compound as claimed in claim 1, where R^3 is $-O-(CH_2)_p-G$ with p equal to 2, 3 or 4.
9. A compound as claimed in claim 1, where R^5 is a 6-membered ring and R^{52} is an optionally substituted phenyl ring.

RECEIVED
SEP 23 2002
TECH CENTER 1600/2900

10. A drug comprising besides conventional vehicles and ancillary substances a compound as claimed in claim 1.
11. A method for treating a disorder in which pathologically elevated PARP activities occur, said method comprising administering an effective amount of a compound of the formula I as claimed in claim 1 to a mammal suffering from said disorder.
12. The use of compounds of the formula I as claimed in claim 11 wherein the disorder is a neurodegenerative disease or involves neuronal damage.
13. The method as claimed in claim 12, wherein the neurodegenerative disease or neuronal damage is induced by ischemia, trauma or massive bleeding.
14. The method as claimed in claim 11 wherein the disorder is stroke or craniocerebral trauma.
15. The method as claimed in claim 11 wherein the disorder is Alzheimer's disease and Huntington's disease.
16. The method as claimed in claim 11 wherein the disorder is damage due to ischemia.
17. The method as claimed in claim 11 wherein the disorder is epilepsy.
18. The method as claimed in claim 11 wherein the disorder is damage to the kidneys after renal ischemia, damage caused by drug therapy or damage resulting after kidney transplants.
19. The method as claimed in claim 11 wherein the disorder is damage to the heart after cardiac ischemia.



RECEIVED
SEP 23 2002
TECH CENTER 1600/2900

LUBISCH et al., Serial No. 09/830,992

20. The method as claimed in claim 11 wherein the disorder is a microinfarcts.
21. The method as claimed in claim 11 wherein the disorder is under vascularization of critically narrowed coronary arteries.
22. The method as claimed in claim 11 wherein the disorder is an acute myocardial infarct and damage during an after medical or mechanical lysis thereof.
23. The method as claimed in claim 11 wherein the disorder is a tumor or metastasis I thereof.
24. The method as claimed in claim 11 wherein the disorder is sepsis of multi-organ failure.
25. The method as claimed in claim 11 wherein the disorder is an immunological disease.
26. The method as claimed in claim 11 wherein the disorder is diabetes mellitus.